Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00286351

Enrollment

Registered

2006-02-03

Start date

2005-01-31

Completion date

Unknown

Last updated

2007-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Brief summary

Does a combination of Arimidex and Zoladex make endometriomas shrink and how is the following IVF outcome

Interventions

DRUGCombined treatment with Arimidex and Zoladex before IVF

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Endometrioma(s)with a size of 20-70 mm, persisted for at least 3 cycles * Couples with indication and wish for IVF/ICSI * Age of women: 20-40 years * Regular menstrual cycle within normal range (21-35 days) * Body Mass Index (BMI): 18-30 kg/m2

Exclusion criteria

* History with osteoporosis, liver-, kidney- or heart disease or thromboembolic disease * Treatment of endometriosis with GnRH agonist during the last 3 month

Design outcomes

Primary

Measure	Time frame
size of endometriomas after 2½ month of combined downregulation	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026